Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Yale research fuels biotech advances

Intravenous injection of bone marrow derived stem cells in patients with spinal cord injuries led to significant improvement in motor functions, researchers from Yale University...

| By Kelley Gipson

Women in Bio announces Connecticut chapter

The Women in Bio board of directors has voted unanimously to grant chapter status to the vibrant WIB-Connecticut community. Formerly an extension of the WIB-Metro...

| By Kelley Gipson

UConn and startups active in bioscience

UConn startup 3BC is using cutting-edge research to produce high-quality hemp products … more A Uconn researcher is advancing tissue engineering … more UConn startup...

| By Kelley Gipson

Merck will help make J&J coronavirus vaccine

The pharmaceutical giant Merck & Co will help manufacture the new Johnson & Johnson coronavirus vaccine under an unusual deal, brokered by the White House,...

| By Kelley Gipson

Murphy names CT Biotech ‘Innovator of the Month’

U.S. Senator Chris Murphy (D-Conn.) has named Connecticut Biotech of South Windsor  “Innovator of the Month.” Founded during the early days of the COVID-19 pandemic,...

| By Kelley Gipson

Biohaven drug shows promise against COVID-19

Biohaven Pharmaceuticals will advance its newly acquired COVID-19 treatment into human testing after lab studies showed it worked against multiple strains of the coronavirus —...

| By Kelley Gipson

CT firms featured in lists of ‘best’ companies

In its list of “The Top 25 Biotech CEOs of 2021,” the Healthcare Technology Report includes John Houston of Arvinas, citing the company for expanding “the...

| By Kelley Gipson

CT vaccine rollout now to be prioritized by age

Connecticut Governor Ned Lamont is changing the state’s current playbook for the COVID-19 vaccine rollout. The state had prioritized people with underlying medical conditions and...

| By Kelley Gipson

Antibiotics investment fund taps Henry Skinner

An ambitious pharmaceutical industry venture to tackle antibiotic resistance has hired its first chief executive officer and received $140 million in additional funding commitment. The...